We are live on ! Find out more
THRX

Theseus Pharmaceuticals, Inc. Common Stock
THRX

Delisted

THRX was delisted on the 13th of February, 2024.

Back to rankings

1 hedge funds and large institutions have $0 invested in Theseus Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 70 → 1 (-69)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $146M → $0 (-$146M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 69

Holders
1
Holders Change
-69
Holders Change %
-98.57%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
69
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$53.8K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$71.7M
2
FCMV
Foresite Capital Management V
California
-$16.6M
3
TCM
Tang Capital Management
California
-$13.2M
4
FLSM
Frazier Life Sciences Management
California
-$8.58M
5
BlackRock
BlackRock
New York
-$5.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
– -$71.7M -17,713,600 Closed
FCMV
2
Foresite Capital Management V
California
– -$16.6M -4,108,796 Closed
TCM
3
Tang Capital Management
California
– -$13.2M -3,255,026 Closed
FLSM
4
Frazier Life Sciences Management
California
– -$8.58M -2,118,051 Closed
BlackRock
5
BlackRock
New York
– -$5.77M -1,425,234 Closed
BCM
6
BML Capital Management
Indiana
– -$4.49M -1,108,320 Closed
Vanguard Group
7
Vanguard Group
Pennsylvania
– -$3.22M -795,549 Closed
OFM
8
Omega Fund Management
Massachusetts
– -$2.88M -711,479 Closed
LCM
9
Lynx1 Capital Management
Puerto Rico
– -$2.84M -702,415 Closed
HCM
10
Highbridge Capital Management
New York
– -$2.5M -616,860 Closed
Geode Capital Management
11
Geode Capital Management
Massachusetts
– -$1.65M -407,822 Closed
State Street
12
State Street
Massachusetts
– -$1.5M -371,156 Closed
BCM
13
Beryl Capital Management
California
– -$1.17M -288,887 Closed
MI
14
MMCAP International
Cayman Islands
– -$1.12M -277,303 Closed
Renaissance Technologies
15
Renaissance Technologies
New York
– -$1.1M -271,600 Closed
Morgan Stanley
16
Morgan Stanley
New York
– -$735K -181,582 Closed
ACM
17
ADAR1 Capital Management
Texas
– -$708K -174,715 Closed
Northern Trust
18
Northern Trust
Illinois
– -$626K -154,580 Closed
Ensign Peak Advisors
19
Ensign Peak Advisors
Utah
– -$564K -139,196 Closed
LCM
20
Laurion Capital Management
New York
– -$530K -130,945 Closed
DA
21
Denali Advisors
California
– -$420K -103,800 Closed
Acadian Asset Management
22
Acadian Asset Management
Massachusetts
– -$388K -96,208 Closed
N
23
Nuveen
North Carolina
– -$332K -81,898 Closed
Bank of New York Mellon
24
Bank of New York Mellon
New York
– -$241K -59,553 Closed
BCM
25
Bridgeway Capital Management
Texas
– -$231K -57,000 Closed
1
2 3

THRX Hedge Fund Activity: Q1 2024 in Review

1 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q1 2024, worth a combined $0 — down 100% from $146M a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of THRX and 0 opened new positions — a net loss of 69 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Goldman Sachs, adding an estimated $53.8K. The largest seller was OrbiMed, exiting entirely with an estimated $71.7M sold.

  • 1 institutional investor held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q1 2024, down from 70 in Q4 2023.
  • Funds reported $0 of Theseus Pharmaceuticals, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 69 closed out, a net change of -69 holders.
  • The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Goldman Sachs, an estimated $53.8K added.
  • The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was OrbiMed, an estimated $71.7M sold.

Based on aggregated 13F filings for Q1 2024.